Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chronic granulomatous disease.

Paul G Heyworth1, Andrew R Cross, John T Curnutte

  • 1DNAX Research Incorporated, 901 California Avenue, Palo Alto, CA 94304, USA. paul.heyworth@dnax.org

Current Opinion in Immunology
|September 23, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hemostatic Efficacy and Anti-FXa (Factor Xa) Reversal With Andexanet Alfa in Intracranial Hemorrhage: ANNEXA-4 Substudy.

Stroke·2021
Same author

Andexanet versus prothrombin complex concentrates: Differences in reversal of factor Xa inhibitors in in vitro thrombin generation.

Research and practice in thrombosis and haemostasis·2020
Same author

A phase 2 PK/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers.

Blood advances·2020
Same author

Semi-automatic measurement of intracranial hemorrhage growth on non-contrast CT.

International journal of stroke : official journal of the International Stroke Society·2019
Same author

Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors.

The New England journal of medicine·2019
Same author

Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study.

American journal of hematology·2018
Same journal

Noncanonical ion channel signaling in neurovascular barrier regulation and immune cell trafficking.

Current opinion in immunology·2026
Same journal

A blind spot of human T cell immunology: epitope specificity in secondary lymphoid organs.

Current opinion in immunology·2026
Same journal

Germinal center responses at barrier organ sites.

Current opinion in immunology·2026
Same journal

Ocular sarcoidosis: from clinical signs to targeted interventions.

Current opinion in immunology·2026
Same journal

On or within: spatial determinants of antigen handling in the nasal turbinates.

Current opinion in immunology·2026
Same journal

Decoding the complexity of intestinal immunity with spatial transcriptomics.

Current opinion in immunology·2026
See all related articles

Chronic granulomatous disease (CGD) results from mutations affecting phagocyte NADPH oxidase. A small percentage of these mutations offer insights into enzyme function and regulation, revealing novel fusion proteins.

Area of Science:

  • Immunology
  • Genetics
  • Biochemistry

Background:

  • Chronic granulomatous disease (CGD) is a primary immunodeficiency impacting phagocyte function.
  • It leads to severe bacterial and fungal infections due to impaired innate immunity.
  • CGD arises from mutations in genes encoding subunits of the phagocyte NADPH oxidase enzyme.

Purpose of the Study:

  • To analyze the functional impact of identified Chronic granulomatous disease mutations.
  • To investigate the relationship between protein structure and function in phagocyte NADPH oxidase.
  • To explore novel findings regarding gene recombination events in CGD.

Main Methods:

  • Analysis of 410 identified Chronic granulomatous disease mutations.
  • Categorization of mutations based on protein expression levels (complete loss, partial loss, normal inactive protein).

Related Experiment Videos

  • Review of recent studies on gene recombination events in the NCF-1 gene.

    • Main Results:

    • 95% of mutations cause complete or partial loss of NADPH oxidase subunits, offering limited structure-function insights.
    • The remaining 5% of mutations result in normal levels of inactive protein, providing valuable functional data.
    • Recombination events in the NCF-1 gene can lead to the absence of p47-phox and a novel fusion protein.

    Conclusions:

    • Mutations causing partial or complete protein loss in CGD are most common but less informative about enzyme function.
    • Mutations preserving inactive protein levels are crucial for understanding NADPH oxidase regulation and catalysis.
    • Gene recombination in NCF-1 presents a unique mechanism in CGD pathogenesis, potentially generating novel proteins.